Clinical trial
Study Comparing Lapatinib (GW572016) And Letrozole Versus Letrozole In Subjects…
NCT00073528 · Novartis Pharmaceuticals, Industry · Completed
Key facts
| NCT number | NCT00073528 |
|---|---|
| Title | Study Comparing Lapatinib (GW572016) And Letrozole Versus Letrozole In Subjects With Advanced Or Metastatic Breast Cancer |
| Official title | A Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase III Study Comparing GW572016 and Letrozole Versus Letrozole in Subjects With Estrogen/Progesterone Receptor- Positive Advanced or Metastatic Breast Cancer |
| Lead sponsor | Novartis Pharmaceuticals, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Breast Neoplasms |
| Intervention type | Drug |
| Interventions | Lapatinib, Letrozole, Placebo |
| Enrollment | 1,286 |
| Start date | Dec 9, 2003 |
| Primary completion | Jun 3, 2008 |
| Completion | Mar 22, 2018 |
| First posted | Nov 26, 2003 |
| Last update posted | Feb 24, 2021 |
| Countries | Argentina, Australia, Brazil, Bulgaria, Canada, Chile, Colombia, Croatia, Czechia, Denmark, France, Germany and 17 more |
At a glance
- 100–999 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: